Description: CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Home Page: www.cervomed.com
20 Park Plaza
Boston,
MA
02116
United States
Phone:
617 744 4400
Officers
| Name | Title |
|---|---|
| Dr. John J. Alam M.D. | Co-Founder, CEO, President & Director |
| Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder & Director |
| Mr. William Robert Elder J.D. | CFO & General Counsel |
| Dr. Robert J. Cobuzzi Jr., Ph.D. | COO & Director |
| Ms. Kelly Blackburn M.H.A. | Senior Vice President of Clinical Development |
| Dr. Mark A. De Rosch Ph.D. | SVP of Regulatory & Government Affairs & Program Management |
| Dr. Claudia Ordonez M.D. | Senior Vice President of Medical Science |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.349 |
| Price-to-Sales TTM: | 1.5988 |
| IPO Date: | 2016-01-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |